Christopher Slachta Joins Cytovale as Chief Operating Officer
SAN FRANCISCO, March 4, 2024 /PRNewswire/ -- Cytovale®, a commercial-stage medical diagnostics company focused on advancing early detection technologies to diagnose fast-moving and immune-mediated diseases, today announced the appointment of Christopher Slachta, Ph.D., MBA, as the company's chief operating officer (COO). With more than 20 years of experience in the medical device and diagnostic industry, Slachta will lead operations as Cytovale ramps up production of its FDA-cleared rapid sepsis diagnosis test — IntelliSep®.
- SAN FRANCISCO, March 4, 2024 /PRNewswire/ -- Cytovale ® , a commercial-stage medical diagnostics company focused on advancing early detection technologies to diagnose fast-moving and immune-mediated diseases, today announced the appointment of Christopher Slachta, Ph.D., MBA, as the company's chief operating officer (COO).
- With more than 20 years of experience in the medical device and diagnostic industry, Slachta will lead operations as Cytovale ramps up production of its FDA-cleared rapid sepsis diagnosis test — IntelliSep ® .
- Slachta joins Cytovale after serving 12 years at Abbott, most recently as divisional vice president of global operations and supply chain, molecular diagnostics.
- Ajay and his team have developed a proven solution with the potential to make a huge clinical impact on patient care," said Slachta.